BASEL, Switzerland, Feb. 21, 2014 (GLOBE NEWSWIRE) -- Auris Medical today announced enrollment of the first patient into in the TACTT31 clinical trial - a phase 3 study designed to evaluate the efficacy, safety and tolerability of intratympanic injections of AM-101 in the treatment of acute peripheral tinnitus following traumatic cochlear injury or otitis media. The TACTT3 study will enroll 600 patients at more than 60 European sites: 300 during the acute tinnitus stage (up to 3 months from onset) and 300 during the post-acute tinnitus stage (4 to 12 months from onset).